Aim 1. Discover and Develop Targeted Therapeutics Engaging Key Cancer Pathways. CTT members discover antineoplastic properties of natural and synthetic products, identify new “druggable” targets by integrating high throughput screening approaches with a variety of genetic, transcriptomics, proteomics and metabolomic approaches to develop, refine, or combine compounds that interact with key cancer pathways to address CA priority cancers.
Aim 2. Identify and Develop Novel Biomarkers, Assays, Materials, and Methods to Improve Therapeutic Outcomes. CTT members develop, characterize, and validate multi-omics driven prognostic and/or predictive biomarkers relevant to improving outcomes in cancer patients. Development of novel tools and assays, microfluidics devices and both classical and novel spatial-omics approaches provide opportunities to impact patient care or design therapeutic strategies to advance precision oncology. Research being conducted maintains a goal of improving the impact of personalized therapies for patients.
Aim 3. Apply Novel Concepts for Improvement of Cancer Therapy through Translation. Engaging members in all 4 UFHCC programs through disease group mini retreats, program meetings, and the i2T3, discoveries ranging from screening interventions to new therapies are effectively and efficiently translated into clinical trials.
